65,437 trials
Pneumococcal Vaccines
Primary: Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series…
Vaccines, Pneumococcal
Primary: Percentage of Participants Achieving a Meningococcal C Serum Bactericidal Assay (SBA) Titer ≥1:8 and Predefined Antibody Levels for Pertussis and Haemophilus Influenzae…
Anemia
Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 11.22; 11.33; 0.10 g/dL
Pneumococcal Infections
Primary: Percentage of Participants Achieving Antibody Level ≥0.35μg/mL After Vaccination — 100.0; 100.0; 99.3; 98.8 percentage of participants
Screening Test · Endoscopy · Colon Disease
Primary: Percentage of Successful Cecal Intubations (Crude) — 95.3 percentage of colonoscopies performed
Bronchial Asthma
Primary: Morning Peak Expiratory Flow (PEF) — 12.88; 13.78; 4.59 Liters/min
Diabetes Mellitus, Type 2
Primary: HbA1c: Change From Baseline to Study Endpoint — -1.72; -1.13 percent — p=<0.0001
Vaccines, Pneumococcal
Primary: Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC+P80 Group Relative to 13vPnC-80 Group After the Infant Series — 93.3; 94.1; 60.9; 66.4…
Healthy Subjects · Pneumococcal Infections
Primary: Percentage of Participants Reporting Pre-Specified Local Reactions — 34.5; 43.5; 28.2; 36.4 percentage of participants
Vaccines, Pneumococcal
Primary: Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hemophilus Influenza Type b (Hib), Poliomyelitis (Type 1, 2, 3), Pertussis Toxin…
Cellulitis
Primary: Relative Efficacy — 62; 60 participants — p=<0.05
Post-operative Surgical Site Infections
Primary: Number of Patients With a Clinically Diagnosed Infection — 0; 0 participants
Squamous Cell Carcinoma of the Head and Neck
Primary: Best Overall Response (BOR) — 68.2 percentage of participants
Idiopathic Parkinson's Disease
Primary: UPDRS Part III OFF — -7.21; -6.91 units on a scale
High-Risk Melanoma
Primary: Immunologic Response Rate — 2; 0; 0; 3 Participants